Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
NCT ID: NCT04783935
Last Updated: 2025-01-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
219 participants
INTERVENTIONAL
2021-03-10
2023-09-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
NCT04776213
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
NCT03364036
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
NCT03369665
ATX-MS-1467 in Multiple Sclerosis
NCT01973491
Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
NCT03961204
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mavenclad®
Mavenclad®
No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568\_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mavenclad®
No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568\_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Capable of giving signed informed consent
Exclusion Criteria
* Participation in other studies/trials
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Responsible
Role: STUDY_DIRECTOR
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Liverpool Hospital
Liverpool, , Australia
John Hunter Hospital
New Lambton, , Australia
Klinikum Klagenfurt
Klagenfurt, , Austria
Paracelsus Medical University Salzburg
Salzburg, , Austria
University of Alberta
Edmonton, , Canada
Children's Hospital, London Health Sciences Centre- Pediatrics
London, , Canada
Montreal Neurological Hospital
Montreal, , Canada
MS Clinical Trials Group
Vancouver, , Canada
Fakultni nemocnice Brno
Brno, , Czechia
Fakultni nemocnice u sv. Anny v Brne
Brno, , Czechia
FN Hradec Kralove
Hradec Králové, , Czechia
Nemocnice Pardubickeho kraje, a.s. Pardubicka nemocnice
Pardubice, , Czechia
Fakultni nemocnice v Motole
Prague, , Czechia
Tampere University Hospital
Tampere, , Finland
Turku University Hospital
Turku, , Finland
CHU de Montpellier Hôpital Gui de Chauliac- Département de Neurologie
Montpellier, , France
CHU Nice - Hôpital Pasteur
Nice, , France
CHU Nîmes
Nîmes, , France
CHU de Poissy
Poissy, , France
CHU de Pontchaillou
Rennes, , France
Hôpital Civil
Strasbourg, , France
Universitätsklinikum Carl Gustav Carus
Dresden, , Germany
Universitätsklinikum Essen
Essen, , Germany
Neurologische Praxis Eppendorf
Hamburg, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Klinik und Poliklinik fur Neurologie
Leipzig, , Germany
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo
Szeged, , Hungary
Barzilai Medical Center
Ashkelon, , Israel
Rambam MC
Haifa, , Israel
Sheba Medical Centre
Tel Litwinsky, , Israel
Università "G. D'Annunzio" Chieti-Pescara Ospedale Cliniciz
Chieti, , Italy
Dipartimento di internistica clinica e sperimentale "Flaviano Magrassi"Università degli studi della Campania "Luigi Vanvitelli"
Napoli, , Italy
IRCSS Neuromed Istituto Neurologico Mediterraneo
Pozzilli, , Italy
Samodzielny Publiczny Szpital Kliniczny nr 7 SUM
Katowice, , Poland
Indywidualna Praktyka Lekarska Prof. Konrad Rejdak
Lublin, , Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanislawa Szyszko SUM w Katowicach
Zabrze, , Poland
Hospital de Cruces
Barakaldo, , Spain
Hospital Vithas NISA Sevilla
Castilleja de la Cuesta, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, , Spain
Hospital La Fe
Valencia, , Spain
Sahlgrenska Universitetssjukhus
Gothenburg, , Sweden
Akademiskt Specialist Centrum - Centrum för Neurologi,
Stockholm, , Sweden
Queen Elizabeth Hospital
Birmingham, , United Kingdom
University Hospital of Wales
Cardiff, , United Kingdom
Sheffield Teaching Hospitals Sheffield
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, Chan A, Hodgkinson S, Prat A, Leocani L, Sellebjerg F, Vermersch P, Jin H, Sponton L, Chudecka A, Gardner L, De Stefano N. Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study. Ther Adv Neurol Disord. 2025 Jul 31;18:17562864251351760. doi: 10.1177/17562864251351760. eCollection 2025.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Trial Awareness and Transparency website
Medical Information Location Map - Med Info Contacts
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-003995-42
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MS700568_0157
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.